1. Minimal in vivo requirements for developmentally regulated cardiac long intergenic non-coding RNAs.
- Author
-
George MR, Duan Q, Nagle A, Kathiriya IS, Huang Y, Rao K, Haldar SM, and Bruneau BG
- Subjects
- Animals, Gene Deletion, Heart Defects, Congenital embryology, Heart Defects, Congenital genetics, Mice, Mice, Mutant Strains, RNA, Long Noncoding genetics, Cell Differentiation, Epigenesis, Genetic, Gene Expression Regulation, Developmental, Heart embryology, Myocardium metabolism, RNA, Long Noncoding biosynthesis
- Abstract
Long intergenic non-coding RNAs (lincRNAs) have been implicated in gene regulation, but their requirement for development needs empirical interrogation. We computationally identified nine murine lincRNAs that have developmentally regulated transcriptional and epigenomic profiles specific to early heart differentiation. Six of the nine lincRNAs had in vivo expression patterns supporting a potential function in heart development, including a transcript downstream of the cardiac transcription factor Hand2 , which we named Handlr ( Hand2 -associated lincRNA), Rubie and Atcayos We genetically ablated these six lincRNAs in mouse, which suggested genomic regulatory roles for four of the cohort. However, none of the lincRNA deletions led to severe cardiac phenotypes. Thus, we stressed the hearts of adult Handlr and Atcayos mutant mice by transverse aortic banding and found that absence of these lincRNAs did not affect cardiac hypertrophy or left ventricular function post-stress. Our results support roles for lincRNA transcripts and/or transcription in the regulation of topologically associated genes. However, the individual importance of developmentally specific lincRNAs is yet to be established. Their status as either gene-like entities or epigenetic components of the nucleus should be further considered., Competing Interests: Competing interestsB.G.B. is a co-founder of and owns equity in Tenaya Therapeutics. M.R.G. is an employee of and owns equity in Vascugen. S.M.H. is an executive and shareholder of Amgen and a co-founder with equity stake in Tenaya Therapeutics. These interests are not related to the work described here., (© 2019. Published by The Company of Biologists Ltd.)
- Published
- 2019
- Full Text
- View/download PDF